₹821cr income; ₹202cr EBITDA; ₹65cr PAT
Margins improved, but financing costs rose
Watch: Watch cash and acquisition economics
Home / Research / Anupam Rasayan India Limited
₹821cr income; ₹202cr EBITDA; ₹65cr PAT
https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b67d0e9f-14cb-4571-b840-c9634b33f3b5.pdf
https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b67d0e9f-14cb-4571-b840-c9634b33f3b5.pdf
https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b67d0e9f-14cb-4571-b840-c9634b33f3b5.pdf
https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b67d0e9f-14cb-4571-b840-c9634b33f3b5.pdf
Margins improved, but financing costs rose
Watch: Watch cash and acquisition economics
Different from operating revenue
Watch: Maintain consistent accounting basis
Richer performance-material mix
Watch: Check sustainability
Depreciation and finance cost matter
Watch: Track after-tax cash earnings
Period: quarter ended 30 September 2026. Stance: WATCH. All monetary figures below are Indian rupees in crore unless stated otherwise. [T] is accepted earnings-call transcript issuer document; [P] is accepted investor presentation issuer document. This is an issuer-source analytical brief, not independent statutory or valuation certification.
The company reported consolidated Q2 total income of ₹821 crore, EBITDA of ₹202 crore, and profit after tax of ₹65 crore, against ₹739 crore, ₹144 crore, and ₹57 crore a year earlier. The business mix was approximately 42% life-science specialty chemicals, 28% performance materials and 29% other fluorinated products. The main investment tension is that operating profit has strengthened but reported finance costs and depreciation are rising, and a major pharmaceutical acquisition entered the consolidated balance sheet only at the end of the quarter. [T][P]
Key takeaways
These are positive operating developments, but they are not yet proof that all acquisition capital will earn satisfactory returns. [P]
The company's purchase of 50.07% of Bliss GVS Pharma closed on 28 September 2026. Management explained that the acquired balance sheet was consolidated at September-end while only three days of Bliss operating results entered Q2 earnings.
This creates an important comparability trap: a September consolidated balance sheet is already enlarged, whereas the Q2 income statement is not a full-quarter depiction of the acquired group. Neither the quarterly margin nor the new balance sheet should be mechanically annualized into an acquisition-return estimate.
[T]
Management said the portfolio of long-term contracts and letters of intent amounted to approximately ₹17,496 crore. This is an indication of customer engagement over multiple years, not recognized sales, committed cash receipts, or a guaranteed backlog of equivalent legal enforceability. The distinction between signed supply commitments, nonbinding intentions, product qualifications and actual deliveries is critical to valuation. [T]
The investment decision remains WATCH. Before assigning an attractive multiple to the improved EBITDA, investors need to normalize the prior-year standalone one-time sale, reconcile acquisition accounting, estimate the financing burden of new debt and nonvoting capital, and observe cash generation across the enlarged group. No market price, diluted share count or independently verified enterprise value has been assembled for this brief; no target price is asserted.
Key takeaways
These are consolidated issuer figures and should not be confused with the separately disclosed ₹413 crore standalone total revenue, ₹141 crore standalone EBITDA and ₹46 crore standalone PAT. [P]
At the operating level, material costs were ₹398 crore versus ₹474 crore a year earlier, while employee expenses rose from ₹17 crore to ₹68 crore and other expenses from ₹104 crore to ₹144 crore. A changed acquisition perimeter and product mix can alter line-item comparability; it would be misleading to attribute the entire gross-profit improvement to procurement efficiency alone.
Management associated the EBITDA-margin increase with greater contributions from performance materials and pharmaceutical products. [P][T]
Below EBITDA, the income statement reveals why PAT rose more slowly. Q2 depreciation increased from ₹32 crore to ₹57 crore, and finance cost increased from ₹36 crore to ₹56 crore. EBIT was ₹146 crore versus ₹112 crore, while profit before tax was ₹89 crore versus ₹76 crore. After tax of ₹24 crore, reported PAT was ₹65 crore. This earnings bridge shows real operating improvement but also greater asset intensity and financing expense. [P]
For H1 FY27, consolidated total income was ₹1,489 crore versus ₹1,230 crore, EBITDA ₹377 crore versus ₹273 crore, and PAT ₹116 crore versus ₹106 crore. H1 revenue from operations was ₹1,461 crore against ₹1,217 crore.
Depreciation rose to ₹113 crore from ₹63 crore, and finance costs to ₹105 crore from ₹72 crore. The company reports H1 EBITDA margin of approximately 25%, versus 22%. Higher EBITDA did not flow through proportionately to PAT.
[P]
Management noted a ₹180 crore one-off standalone sale in Q2 FY26, which distorts the year-on-year standalone revenue comparison. It should not be subtracted indiscriminately from consolidated totals or treated as an adjusted EBITDA reconciliation without matching cost information.
Similarly, the 28 September Bliss acquisition requires pro-forma analysis for an apples-to-apples consolidated comparison, but this brief does not fabricate pro-forma full-quarter revenue or profit. [T][P]
The issuer presentation's highlights include a ₹812 crore description of highest-ever quarterly revenue in one narrative slide, while its consolidated financial table reports ₹821 crore total income and ₹806 crore revenue from operations. This report uses the explicit financial table basis and preserves the distinction, rather than silently mixing the headline and accounting categories. [P]
Key takeaways
The sustained weight of performance materials is relevant because management identified this segment as a contributor to higher consolidated margins. [T]
Anupam's custom-synthesis platform historically converts customer chemistry requirements into commercial manufacturing processes. Differentiation may come from fluorination expertise, continuous-flow processes, qualification cycles and customer-specific production assets.
These capabilities can create switching costs, but a long-term contract is only economically valuable if pricing, minimum volume, raw-material pass-through and plant utilization together deliver cash margins. No unsupported product-level gross margins are assigned in this report.
The company highlighted commercializing ETFE using continuous-flow chemistry, which it regards as evidence of moving specialized chemistry from process development into commercial production. The analytical question is whether ETFE volumes, yields and contribution margins grow beyond initial commercialization. A technology milestone does not by itself imply that a full production line has reached steady-state utilization or that customer demand is guaranteed. [T]
A newly signed six-year supply agreement with a leading US specialty-metal manufacturer gives exposure to a new industrial application in the geological-resources sector. This could diversify end-market demand beyond agrochemicals, but the issuer did not provide a detailed quarterly delivery schedule or contract margin in the accepted excerpts.
Investors should therefore monitor first commercial deliveries and customer concentration rather than booking all potential agreement value as current revenue. [T][P]
The Bliss GVS acquisition extends the platform into finished dosage formulations and international pharmaceutical distribution. Management described more than 150 brands and established manufacturing capabilities at Bliss.
In principle, combining intermediates, custom synthesis and finished formulations could improve cross-selling and value capture. In practice, regulatory approvals, product registration, market access, procurement coordination and integration costs determine whether the vertical integration creates incremental cash returns.
[T]
Jayhawk Fine Chemicals adds US manufacturing exposure and advanced custom-synthesis capabilities, while Tanfac contributes a different fluorochemicals footprint. These businesses are not economically identical: geographic costs, customer contract structures, input prices and capital needs differ. The combined group should be judged by segment-level return on capital and cash conversion, not merely by the breadth of product labels. [T]
Key takeaways
Without that separation, investors may mistake consolidation effects for organic growth. [T]
The funding structure was unusual enough to warrant explicit attention. Management described a ₹300 crore term loan and ₹1,450 crore of non-controlling, non-voting financing instruments raised from investors led by Bain Capital, alongside Trust Group and Investec.
These are disclosed transaction funding components, not a complete independently reconstructed purchase-price allocation. The economic rights, cash distributions, redemption terms and priority of the nonvoting instruments matter for ordinary equity holders.
[T]
In analyst Q&A, management said it was still exploring additional API-related acquisition opportunities, but had no specific target to announce. The absence of a public commitment should not be turned into an assumed future transaction.
Analysts also challenged the pace of scaling Bliss's CDMO opportunity. Management described more active joint customer discussions following the acquisition, but discussion intensity is not signed revenue.
Evidence of conversion requires commercial orders, manufacturing readiness and contribution after integration costs. [T]
Management also emphasized Jayhawk margin optimization through cost initiatives. That is a management objective rather than a realized consolidated margin bridge. An investor should request a transparent sequence of Jayhawk profitability, integration spending, customer wins and foreign-exchange effects over subsequent quarters. If a business is improving, the improvement should appear in identifiable operating metrics, not only in a group-wide EBITDA percentage. [T]
The company reported adding three products during Q2, taking its standalone portfolio to more than 125 products. A larger catalogue is useful only if commercialized products contribute material recurring revenue. Track launch-to-qualification time, annualized revenue per new product, batch yields, customer dependence and plant capacity occupied by the new molecules. Product count alone is not an earnings forecast. [P]
Management expressed a goal of lowering revenue cyclicality as pharmaceutical and performance-material contributions grow over four to eight quarters. This is forward-looking. It could be falsified by continued volatility in orders, high customer concentration, poor cash collection or an inability to turn research and acquired capabilities into repeat business. The investment process should record the original promise and compare it with subsequent quarterly evidence. [T]
Key takeaways
[T][P]
Excluding the newly consolidated Bliss balance sheet, management said its working-capital cycle improved from approximately 276 days to 271 days. A five-day reduction is directionally positive, but 271 days remains a long cash cycle for a rapidly expanding specialty-chemicals group.
Inventory qualification, export receivables and customer-specific batch production can absorb capital. The next two quarters should show whether this improvement persists after the acquired operations are included on a comparable basis.
[T]
The September consolidated balance sheet reports inventories ₹2,089 crore versus ₹1,775 crore in March and trade receivables ₹1,582 crore versus ₹959 crore. Cash and cash equivalents were ₹764 crore versus ₹394 crore.
These changes cannot be attributed solely to organic sales growth because Bliss's balance sheet was consolidated near period-end. The relevant comparison requires acquisition-adjusted working capital and cash-flow changes, not simply the raw March-to-September difference.
[P]
The same balance sheet shows long-term borrowings ₹853 crore versus ₹511 crore, and short-term borrowings ₹1,605 crore versus ₹1,304 crore. Their simple sum was ₹2,458 crore at September-end versus ₹1,815 crore in March, but this is not an independently certified net-debt definition and excludes any other debt-like claims or instrument economics.
Non-controlling interest rose to ₹2,148 crore from ₹1,296 crore; the structure of the Bliss financing is relevant when interpreting this change. [P][T]
A purely illustrative subtraction of the disclosed cash-and-equivalents line from these two borrowing categories yields ₹1,694 crore at September-end, versus ₹1,421 crore in March. This is a derived partial net-borrowing proxy, not issuer-reported net debt; restricted cash, investments, leases and nonvoting instruments could alter a full economic net-debt analysis. Investors should avoid quoting it as the company's official leverage. [P]
The cost of the enlarged capital structure is already visible in the P&L: Q2 finance cost ₹56 crore versus ₹36 crore, and H1 finance cost ₹105 crore versus ₹72 crore. The combination of rising depreciation and financing cost can reduce the benefit of EBITDA expansion for equity owners.
No unsupported capex total, project payback or acquisition internal rate of return is asserted. The next full-quarter filing should reconcile operating cash, actual capex, debt drawdowns, acquisition cash uses and financing-instrument obligations.
[P]
Key takeaways
Bull case — only if execution and cash validate the thesis. New high-value chemical products move from technical qualification to recurring shipments; the six-year US industrial agreement begins commercial deliveries; ETFE and fluorinated products earn satisfactory margins; Jayhawk profitability improves; and Bliss's formulations and CDMO network contributes cash after integration. Working-capital days fall on a comparable basis while finance costs remain manageable. These conditions could improve sustainable returns on capital, but no price target follows automatically.
Bear case — capital intensity overwhelms mix improvement. Acquisition integration absorbs management time, new customer agreements convert more slowly than expected, receivables expand, and specialized chemical capacity remains underutilized. The ₹1,450 crore nonvoting instrument could have economic obligations not visible from a simple ordinary-share valuation.
Higher depreciation and interest then absorb EBITDA gains. The company's diversification narrative may remain strategically plausible even as equity cash returns disappoint. [T][P]
What would falsify the constructive thesis? Repeated weak conversion of the stated ₹17,496 crore contract-and-LOI portfolio into revenue; no measurable improvement in Bliss/Jayhawk cash economics; worsening working-capital days; further growth in borrowings without commensurate operating cash; or persistent growth in EBITDA while PAT and free cash fail to improve. The opposite observations would strengthen confidence.
Critical accounting comparability risks: the prior-year ₹180 crore standalone one-time sale, late-quarter Bliss consolidation, different total-income and operating-revenue definitions, and potential minority/nonvoting financing claims. A company-specific financial model must treat each separately. No unsupported probability weights, peer multiples or price scenarios are supplied.
Key takeaways
Operating scorecard: use Q2 consolidated operating revenue ₹806 crore, total income ₹821 crore, EBITDA ₹202 crore, and PAT ₹65 crore as explicitly labeled baselines. Compare the next quarter on the same consolidated basis and separately disclose the first full-quarter contribution from Bliss. The prior Q2's standalone one-time sale must not be used to inflate a normalized growth claim. [P]
Mix and customer scorecard: track the 42% life-science, 28% performance-materials and 29% other-fluorinated quarterly mix, as well as actual shipments under the US specialty-metal agreement and ETFE commercialization. Demand contract-backed order conversion rather than extrapolating the ₹17,496 crore LOI/contract portfolio. [T][P]
Acquisition scorecard: obtain Bliss's standalone and post-acquisition consolidated operating contribution, its CDMO customer conversion, Jayhawk margin trajectory, and details of the ₹300 crore loan and ₹1,450 crore nonvoting financing. Separate accounting non-controlling interests from ordinary-equity economic claims. Record management's four-to-eight-quarter diversification ambition as a hypothesis to test, not a promised financial outcome. [T]
Cash scorecard: compare subsequent operating cash against the disclosed ₹328 crore H1 baseline, and observe whether the approximately 271-day pre-Bliss working-capital cycle improves on a consistent perimeter. Track inventories, receivables, customer collections and cash after capex. A growing balance sheet can temporarily flatter revenue visibility while making cash generation less predictable. [T][P]
Financing scorecard: follow Q2 finance cost ₹56 crore, H1 ₹105 crore, and September borrowings ₹853 crore long-term plus ₹1,605 crore short-term. Ask for an issuer-reconciled net-debt bridge including leases and the nonvoting instrument's contractual economics. Compare the financing cost of acquisitions with the incremental profit and cash they actually generate. [P]
Upgrade analytical confidence if full-quarter Bliss contribution, higher-value product deliveries and cash conversion improve together. Reduce confidence if working capital, finance cost and capital employed rise faster than durable operating profit. This is a practical monitoring framework, not a price target or forecast.
[T] issuer document, Q2/H1 FY27, Anupam Rasayan management and analyst Q&A. Text-derived third-party access location: . The third-party transcript is not reproduced verbatim.
[P] issuer document, dated 6 November 2026, original BSE filing: https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b67d0e9f-14cb-4571-b840-c9634b33f3b5.pdf .
Both issuer source documents are treated as authoritative source inputs for this issuer-source brief. Issuer guidance, derived arithmetic and reported statutory numbers are distinguished. No independent statutory audit, market valuation, price target, external rights certification or future-performance guarantee is claimed.
https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b67d0e9f-14cb-4571-b840-c9634b33f3b5.pdf
https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b67d0e9f-14cb-4571-b840-c9634b33f3b5.pdf
https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b67d0e9f-14cb-4571-b840-c9634b33f3b5.pdf
This is dated research, not a live market quote. Scenarios and historical performance are not guarantees.